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The risk of celiac disease is strongly associated
with human leukocyte antigen (HLA) DQ2 and to
a lesser extent with HLA DQ8. Although the
pathogenesis of HLA-DQ2-mediated celiac dis-
ease is established, the underlying basis for
HLA-DQ8-mediated celiac disease remains
unclear. We showed that T helper 1 (Th1) re-
sponses in HLA-DQ8-associated celiac pathol-
ogy were indeed HLA DQ8 restricted and that
multiple, mostly deamidated peptides derived
from protease-sensitive sites of gliadin were
recognized. This pattern of reactivity con-
trasted with the more absolute deamidation
dependence and relative protease resistance
of the dominant gliadin peptide in DQ2-
mediated disease. We provided a structural
basis for the selection of HLA-DQ8-restricted,
deamidated gliadin peptides. The data estab-
lished that the molecular mechanisms underly-
ing HLA-DQ8-mediated celiac disease differed
markedly from the HLA-DQ2-mediated form of
the disease. Accordingly, nondietary therapeu-
tic interventions in celiac disease might need to
be tailored to the genotype of the individual.
INTRODUCTION
Celiac disease is a common T cell-mediated disease
caused by dietary gluten and is associated with human
leukocyte antigen (HLA) DQ2 and/or HLA DQ8. HLA DQ8
without HLA DQ2 is present in 6% of patients with celiac
disease, whereas both HLA DQ2 and HLA DQ8 are pres-ent in approximately 10% of patients (Karell et al., 2003).
By contrast, around 95% of patients have HLA DQ2, and
consequently more is known about HLA-DQ2-associated
celiac disease than HLA-DQ8-associated celiac disease.
In HLA-DQ2-associated celiac disease, intestinal T cell
lines and clones are HLA DQ2 restricted and recognize
peptides derived from each of the subfractions of wheat
gluten (a, b, g, and u gliadin; low molecular weight [LMW]
and high molecular weight [HMW] glutenins) and homolo-
gous sequences in rye secalins and barley hordeins
(Anderson et al., 2000; Arentz-Hansen et al., 2000;
Arentz-Hansen et al., 2002; Sjostrom et al., 1998; Vader
et al., 2003a). Pretreatment of wheat gliadin with transglu-
taminase (TG2) increases interferon-g (IFN-g) secretion
and proliferation of HLA-DQ2-restricted gliadin-specific
intestinal T cells (Molberg et al., 1998; van de Wal et al.,
1998a). Fine mapping of HLA-DQ2-restricted determi-
nants has identified a preference for glutamate at anchor
positions P4 or P6, and occasionally P7, corresponding
to glutamine residues susceptible to deamidation by
TG2 (Arentz-Hansen et al., 2000; Arentz-Hansen et al.,
2002; Qiao et al., 2005; Vader et al., 2002b). Nevertheless,
most T cell reactivity in HLA-DQ2-associated celiac dis-
ease is directed toward the immunodominant wheat-
gluten T cell determinants (DQ2-a-I: PFPQPELPY, and
DQ2-a-II: PQPELPYPQ) contained within a single, prote-
ase-resistant a-gliadin peptide (Anderson et al., 2000;
Arentz-Hansen et al., 2000). These determinants are de-
pendent upon the deamidation of a single glutamine at
P4 or P6 for optimal T cell reactivity. The low-affinity inter-
action between the unmodified DQ2-a-I peptide and HLA
DQ2 is substantially enhanced by the deamidation of P6
glutamine, dramatically improving T cell recognition.
Structural studies reveal the importance of a network of
hydrogen bonds in enhancing the binding of the deami-
dated gliadin determinant, DQ2-a-I, to HLA DQ2 (Kim
et al., 2004).Immunity 27, 23–34, July 2007 ª2007 Elsevier Inc. 23
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HLA DQ8 and Celiac DiseaseTable 1. HLA and Patient Characteristics
Subject Age/Sex DQA1 Alleles DQB1 Alleles Serological Equivalent Histology GFD (yr) Gluten Challenge (day)
C1 62/F 03, 505 0301/9–10, 0302 DQ7,8 TVA 4 0.5
C2 44/F 0102/6, 301–3 0602, 0302 DQ6,8 SVA 15 3
C3 36/F 03 0302 DQ8- PVA 12 3
C4 53/F 03, 505 0301/09, 0302 DQ7,8 SVA 15 3
C5 52/M 03, 4 0302, 402 DQ4,8 SVA 5 3
The following abbreviations are used: partial villous atrophy (PVA), subtotal villous atrophy (SVA), total villous atrophy (TVA), and
gluten-free diet (GFD).The corresponding molecular basis for HLA DQ8 in ce-
liac disease is not well understood, and only three distinct
HLA-DQ8-restricted determinants are described for intes-
tinal T cell lines and clones (van de Wal et al., 1998a; van
de Wal et al., 1998b; van de Wal et al., 1999; Tollefsen
et al., 2006). The a-gliadin determinant DQ8-a-I
(EGSFQPSQE) is deamidated at two sites, P1 and P9. No-
tably, DQ8-a-I is derived from a region of a-gliadin that is
susceptible to digestive proteases and is therefore likely
to have a limited half-life and bioavailability for antigen
presentation (Shan et al., 2002). Another deamidation-
dependent g-gliadin determinant has also been recently
described (DQ8-g-I: EQPQQPFPE) in which glutamine at
P1 and P9 are also deamidated (Tollefsen et al., 2006).
The third HLA-DQ8-restricted determinant (DQ8-GLT-I),
a HMW-glutenin sequence (QGYYPTSPQ) (van de Wal
et al., 1999), does not require deamidation for recognition
by gluten-specific intestinal T cell lines, although it is only
targeted in a minority of patients. Accordingly, it remains
unclear whether deamidation is the general rule for HLA-
DQ8-associated celiac disease.
Thus, the present understanding of disease mechanism
in HLA DQ8 celiac disease is based on the systematic
screening of only two gliadin polypeptides (Tollefsen
et al., 2006). To further understand whether the same mo-
lecular processes control the selection of gluten peptides
associated with HLA DQ2 and DQ8 in celiac disease, we
set out to quantify the contribution of known HLA DQ8 de-
terminants to the overall gliadin-specific T cell response,
and to characterize peptides recognized by T cells in-
duced by in vivo gluten exposure with a comprehensive
peptide library encompassing all unique 12-mers within
108 gliadin polypeptide sequences. Having established
that DQ8-a-I is an immunodominant determinant, we
then solved the structure of DQ8-a-I complexed with
HLA DQ8. Our findings suggest that all nondietary thera-
peutic approaches are unlikely to be equally effective in
HLA-DQ2- and HLA-DQ8-associated celiac disease.
RESULTS
Multiple Deamidation-Dependent Gliadin
Determinants in HLA DQ8+ Celiac Disease
In HLA DQ2+ patients with celiac disease on a strict gluten-
free diet, gliadin-specific peripheral blood T cells are rare
before gluten challenge (d0), but 6 days (d6) after com-24 Immunity 27, 23–34, July 2007 ª2007 Elsevier Inc.mencing the gluten challenge, these T cells are readily
quantified by enzyme-linked immunospot (ELISPOT) esti-
mations of IFN-g-producing cells ex vivo. Therefore, we
tooka similar approach inassessing thespecificityofT cells
in HLA DQ8+ celiac disease. The diversity and dominance
patternsof gluten peptide determinants were characterized
in five HLA DQ2DQ8+ (DQA1*03 and DQB1*0302) patients
available for in vivo gluten challenge from a cohort of 295
patients on a strict gluten-free diet (Table 1). (Overall, 12/
295 [4%] were HLA DQ2DQ8+, 24/295 [8%] were HLA
DQ2+DQ8+, and 259/295 [88%] were HLA DQ2+DQ8.)
Peripheral blood mononuclear cells (PBMCs) from the
first two subjects (C1 and C2) assessed on d0 and d6 con-
firmed that challenge with wheat gluten induced T cells
specific for deamidated gliadin in an overnight IFN-g-
ELISPOT assay (Figure 1A). The frequency of spot-forming
units (SFUs) per million PBMCs specific for deamidated
gliadin (total gliadin + TG2) varied between 32 and 557
among the five subjects (C1–C5, Figure 1B). Pretreatment
of gliadin with TG2 consistently increased IFN-g-ELISPOT
responses by more than 10-fold (compare no TG2
with +TG2). Each of the deamidated wheat-gliadin fractions
(a, b, g, andu) was a target of T cells, and their recognition
was enhanced by deamidation (Figure 1B). Typically, dea-
midated g- or u-gliadin was the most active fraction. Al-
though subjects were challenged with wheat gluten, dea-
midated 45 kD, 75 kD, and u-secalin fractions from rye
also stimulated IFN-g-ELISPOT responses comparable
to those of deamidated g- or u-gliadin (data not shown).
In four of the five subjects, preincubation of PBMCs with
DQ mAb, but not DR mAb, inhibited responses to deami-
dated gliadin and each of the gliadin fractions (Figure 1C).
In subject C1, whose PBMC responses were weak, the
presence of DR mAb but not DQ mAb reduced IFN-g-
ELISPOT responses to deamidated gliadin. Preincubation
with both DR mAb and to a lesser degree DQ mAb re-
duced PBMC responses stimulated by tetanus toxoid
(Figure 1C). Hence, peripheral blood T cells induced by
gluten challenge in HLA-DQ8-associated celiac disease
are typically HLA DQ restricted, and preferentially recog-
nize deamidated a-, b-, g-, and u-gliadin.
Hierarchical Deamidation Dependence
in HLA-DQ8-Restricted Gliadin Determinants
Responses to peptides a2:226–240 (PSGQGSFQPS
QQNPQ) and GLT04:721–735 (QGQQGYYPTSPQQSG)
Immunity
HLA DQ8 and Celiac DiseaseFigure 1. In Vivo Gluten Challenge in HLA DQ8+2 Celiac Disease
PBMCs drawn from two HLA DQ8+2 celiac-disease subjects normally on a strict gluten-free diet (GFD) were assessed by IFN-g-ELISPOT assay in
response to deamidated gliadin (100 mg/ml) and gluten determinants (10 mg/ml).
(A) The assay was performed before (day 0) and 6 days after (day 6) the commencement of the gluten challenge (C1, one day challenge; C2, three days
of two 50 g slices of bread/day).
(B and C) Day 6 PBMC IFN-g-ELISPOT responses were measured (B) after deamidation of gliadin and its subfractions (a-, g-, andu-) by pretreatment
with transglutaminase (TG2) and (C) following preincubation of PBMCs with DQ or DR antibody. SFUs/million PBMCs less than 10 (or less than
33 medium alone) were not considered significant (dashed line).encompassing the determinants DQ8-a-I (QGSFQPSQQ)
and DQ8-GLT-I (QGYYPTSPQ), respectively, were also
assessed in the HLA DQ8+ patients with celiac disease
(Figures 2A and 2B). PBMCs were drawn on d6 from
four donors (C2–C5) who responded more strongly to gli-
adin after treatment with TG2 and who were also substan-
tially more responsive to a2:226–240 after pretreatment
with TG2, but were equally responsive to GLT04:721–
735 with or without deamidation (Figure 2A). In subjects
C2–C4, SFUs stimulated by a2:226–240 229Q/E
237Q/E (Q229E Q237E) and GLT04:721–735 were
dose dependent (Figure 2B). The number of SFUs stimu-
lated by a2:226–240 Q229E Q237E at the highest concen-tration tested (100 mg/ml) was between 17% and 33% of
the response obtained to deamidated gliadin (100 mg/ml).
Responses to GLT04:721–735 were equivalent to those
of a2:226–240 Q229E Q237E in subject C2, negligible in
C3, and dominant in C4. Subjects C1 and C5 did not re-
spond substantially to either a2:226–240 or GLT04:721–
735 (responses less than 10 SFUs/million PBMCs equiva-
lent to medium alone). The findings support the variability
in the role of the DQ8-GLT-I determinant in different
patients and of TG2-mediated deamidation in HLA-DQ8-
associated celiac disease.
Detailed analysis of the deamidation dependency of the
DQ8-a-I determinant with a2:226–240 and PBMCs fromImmunity 27, 23–34, July 2007 ª2007 Elsevier Inc. 25
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HLA DQ8 and Celiac DiseaseFigure 2. IFN-g-ELISPOT Responses Stimulated by TG2-Treated a2:226–240 PSGQGSFQPSQQNPQ and GLT04:721–735
QGQQGYYPTSPQQSG
(A) IFN-g-ELISPOT responses in PBMCs from HLA DQ8+2 celiac-disease subjects 6 days after the commencement of the gluten challenge were
assessed to the a-gliadin peptide a2:226–240 (10 mg/ml), the HMW-glutenin peptide GLT04:721-735 (10 mg/ml), and total gliadin (100 mg/ml) with
or without pretreatment with transglutaminase (TG2). Responses below the dashed line (SFUs/million PBMCs less than 10 or less than 33 medium
alone) were not considered significant.
(B) IFN-g-ELISPOT dose-response curves for the deamidated a-gliadin peptide a2:226–240 (PSGEGSFQPSQENPQ) and HMW peptide GLT:722–
736 in the three strongest responding subjects (C2–C4).
(C) IFN-g-ELISPOT dose-response curves for the wild-type, single-glutamate-substituted variants (Q1, E9 and E1, Q9 at either position 208 or 216), or
the doubly deamidated variant (E1, E9) of a2:226–240. Results are expressed as the mean ± the standard error of the mean (SEM) of an individual
subject’s response expressed as the percent of maximal response to an optimal concentration of a2:226–240 Q229E Q237E.subjects C2–C4 showed that the substitutions Q229E or
Q237E alone increased the 50% max responses 10-fold,
but the combination of Q229E and Q237E substitutions in-
creased potency 100-fold (Figure 2C). Five peripheral
blood T cell clones from two donors were raised to
a2:226–240 Q229E Q237E, and each clone proliferated
preferentially to deamidated gliadin (Table S1 in the Sup-
plemental Data available online). Proliferative responses
of clones specific for a2:226–240 were optimally depen-
dent on glutamate substitutions Q229E and Q237E (Fig-
ure S1A). In vitro peptide-binding assays (Vader et al.,
2003b) showed that the binding of the reporter peptide
to isolated HLA DQ8 was not inhibited by wild-type
a2:226–240 even in 100 molar excess (Figure S1B). Incor-
porating the substitutions Q229E and Q237E allowed
a2:226–240 to inhibit the binding of the reporter peptide
to HLA DQ8 by up to 35% at 100 molar excess, and 25-
fold molar excess of competitor peptide was required to
give 50% of the maximal inhibitory effect (35% inhibition)
observed in this assay. However, a2:226–240 Q229E
Q237E is a weaker binder than is the high-affinity HLA DQ8
binder TPO 632–645(Y) (Straumfors et al., 1998); 6.25 mo-
lar excess of TPO 632–645(Y) as compeptitor peptide was26 Immunity 27, 23–34, July 2007 ª2007 Elsevier Inc.required to give 50% of the maximal inhibitory effect (50%
inhibition) observed in this assay. TPO 632–645(Y) pro-
duced a 50% inhibition of reporter peptide binding at
100 molar excess and IC50 was at 6.25 molar excess. To
further assess the role of Q229E and Q237E in enhancing
binding to HLA DQ8, we cultured HLA-DQ8-restricted
CD4+ T cell clones specific for a modified proinsulin pep-
tide (Mannering et al., 2003) with cognate peptide and
50 or 100 molar excess a2:226–240 Q229E Q237E or
wild-type a2:226–240 peptides. T cell responses to the
modified proinsulin peptide detected by IFN-g ELISPOT
were inhibited by a2:226–240 Q229E Q237E but not
wild-type peptide (Figure S1C). Hence, the optimal ago-
nist sequence of a2:226–240 contains glutamate at P1
and P9 in the DQ8-a-I determinant, and these modifica-
tions enhance binding to HLA DQ8.
Subdominant T Cell Determinants
in g-, u-, a-, or b-Gliadins
Our findings above indicated that DQ8-a-I is a commonly
recognized determinant and often contributes substan-
tially to the overall IFN-g-ELISPOT response stimulated
Immunity
HLA DQ8 and Celiac DiseaseTable 2. TG2-Treated 20-mers with Greatest IFN-g-ELISPOT Responses among a 721 Member Peptide Library
Including All Unique 12-mers from 108 a- or b-, g-, and u-Gliadins
Subject
20-mer with
Optimal 16-mer Underlineda C3 C4
SFUs in 1st and (2nd) Gluten Challenge
Gliadin + TG2 228(113) 61(36)
Medium only 16(2) 2(1)
a-Gliadin
P18573 220-239 QPQQQYPSGQGSFQPSQQNPb 28(18)% NR
CAB76961 251-270 VYIPPYCTIAPFGIFGTNYR NR 43(83)%
CAB76960 253-272 AMCNVYIPPYCAMAPFGIFG NR 31(25)%
g-Gliadin
AAK84772 130-149 PQPQQPQLPFPQQPQQPFPQc 39(13)% NR
P08453 94-113 QTQQPQQPFPQQPQQPFPQTc,d 27(15)% NR
AAK84776 102-121 QQPLPQPQQPQQPFPQSQQP 28(14)% 33(36)%
AAK84778 74-93 QQQFIQPQQPFPQQPQQTYP 29(32)% 43(25)%
AAK84772 121-140 QPQQPQQPFPQQQQPLIQPY 26(23)% 28(14)%
P08079 QQFLQPQQPFPQQPQQPYPQd 24(17)% 26(22)%
u-Gliadin
AAG17702 173-192 QQPFPQQPQQPFPQPQQPIPc 40(15)% 16(17)%
AAG17702 239-258 PFPQQPQQPFPQQPQQSFPQ 28(16)% NR
AAG17702 88-107 TPIQPQQPFPQQPQQPQQPFc 32(25)% NR
AAG17702 225-244 PQQPQQPFPLQPQQPFPQQPd 32(28)% 21(36)%
AAG17702 186-205 QPQQPIPVQPQQSFPQQSQQd 31(16)% 20(11)%
AAG17702 80-99 PFTQPQQPTPIQPQQPFPQQc 35(27)% 30(11)%
‘‘NR’’ indicates no response.
a Responses as the percent of gliadin + TG2: 20-mer in the 1st gluten challenge (optimal 16-mer in the 2nd gluten challenge).
b Contains two overlapping 16-mers that are equally active.
c Predicted to be resistant to digestive proteases (Shan et al., 2005).
d All three 16-mers are equally active.by deamidated gliadin. However, T cells in HLA-DQ8-as-
sociated celiac disease clearly recognized determinants
derived from every gliadin fraction. This indicates the im-
portant contribution of other determinants, possibly in-
cluding the recently described DQ8-g-I determinant (Toll-
efsen et al., 2006), to the T cell response directed toward
gliadin in HLA-DQ8-associated celiac disease.
To define additional determinants, we established a
20-mer peptide library encompassing all unique 12-mer
sequences encoded by each of 108 wheat (Triticum
aestivum) gliadin entries (53 a- or b-, 53 g-, and 2 u-
gliadins, Table S2) present in the National Computational
Biology Institute (NCBI) GenBank database. The 20-mers
were synthesized as a 721 member Pepset and were
then pretreated with TG2 and individually assessed for
their capacity to stimulate T cells by IFN-g ELISPOT.
PBMCs were examined from subjects C3 and C4 at d6
after a 3 day wheat-gluten challenge. A second Pepset
library was used to fine map determinants with PBMCs
from the same donors after a second gluten challenge.a-, g-, and u-gliadin peptides that stimulated the great-
est IFN-g-ELISPOT responses, and were confirmed after
a second gluten challenge, are shown in Table 2. Subject
C3 responded to proline- and glutamine-rich peptides
including four g- and two u-gliadin-derived peptides that
encompassed the DQ8-g-I (QQPQQPFPQ) determinant.
Although subject C4 also responded to three of the six
peptides recognized by C3, including the DQ8-g-I deter-
minant, overall C4 showed weaker responses with less
preference for peptides susceptible to deamidation and
responded most strongly to two related a-gliadin 20-mers
that did not contain glutamine and shared the sequence
VYIPPYC[T or A][I or M]APFGIFG. Subject C4 also re-
sponded strongly to GLT04:721–735 encompassing the
DQ8-GLT-I determinant but only weakly to the deamida-
tion-dependent a2:226–240 containing the DQ8-a-I glia-
din determinant (Figures 2A and 2B). Although DQ8-a-I
and VYIPPYC[T or A][I or M]APFGIFG are derived from
protease-sensitive regions of a-gliadin (Shan et al., 2002),
two of the g- and three of the u-gliadin T cell-stimulatoryImmunity 27, 23–34, July 2007 ª2007 Elsevier Inc. 27
Immunity
HLA DQ8 and Celiac DiseaseFigure 3. IFN-g-ELISPOT Responses of PBMCs in HLA DQ8+2 Celiac Disease and Deamidation Dependence
(A) IFN-g-ELISPOT responses from an HLA DQ8+2 homozygous celiac-disease (C3) subject to 13-mers with Gln or Glu at positions corresponding to
predicted HLA DQ8 anchors (P1 and P9) and HLA DQ2 anchors (P4 or P6). The core 9-mer in AAG17702 240–252 (QQPQQPFPQ) corresponds to the
DQ2-g-VII determinant when Gln at P4 is deamidated. Similarly, the core 9-mer in AAK84772 134–146 (QLPFPQQPQ) corresponds to the HLA-DQ2-
restricted determinant (DQ2-g-VI) when Gln at P6 is deamidated.
(B) IFN-g-ELISPOT dose-response curves for two naturally occurring isoforms of a-gliadin a2:226–240 with Ser to Pro substitution at P6 or with two
substitutions Val for Gly at P2 and Ser for Pro at P6. Results are expressed as the mean ± SEM of an individual subject’s IFN-g-ELISPOT response
expressed as the percent of maximal response to an optimal concentration of a2:226–240 Q229E Q237E.peptides (including two encompassing the DQ8-g-I deter-
minant [QQPQQPFPQ]) are derived from sequences pre-
dicted to be resistant to digestive proteases (Shan et al.,
2005).
These findings indicate the polyspecificity of T cell reac-
tivity toward minor determinants and confirm that T cell re-
activity occurs to a mixture of deamidation-dependent
and -independent determinants in DQ8-associated celiac
disease.
Deamidation Preference in g- and u-Gliadins
Resembles the DQ8-a-I Determinant
The IFN-g-ELISPOT response to the immunodominant
DQ8-a-I determinant by donor C3 was similar in magni-
tude to that stimulated by six TG2-treated g- and six u-
gliadin-derived 20-mers. Fine mapping showed that a se-
ries of these peptides, one encompassing the DQ8-g-I
(QQPQQPFPQ) determinant, included glutamine residues
within motifs that promote deamidation by TG2—namely,
glutamine residues located at positions Pro+2, and/or hy-
drophobic amino acid +3, but not Pro+1 or Pro+3 (Fleck-
enstein et al., 2002; Vader et al., 2002a). As shown in
Figure 3A, glutamine-to-glutamate substitutions of P1
and P9 in a series of 13-mer peptides, one including
DQ8-g-I, confirmed a preference for the deamidation of
these sites for the optimal stimulation of polyclonal freshly
isolated peripheral blood T cells. Thus, glutamate substi-
tution at P1 substantially enhanced IFN-g-ELISPOT re-28 Immunity 27, 23–34, July 2007 ª2007 Elsevier Inc.sponses, whereas P9 substitution had an additive effect
in the two u-gliadin 13-mers but not in the g-gliadin pep-
tide. Interestingly, in addition to the DQ8-g-I determinant
sequence (QQPQQPFPQ), which corresponds to the
HLA-DQ2-restricted determinant DQ2-g-VII (QQPQQ
PFPQ), a second sequence (QLPFPQQPQ) recognized
by the HLA DQ8 homozygous donor also corresponded
to an HLA-DQ2-restricted determinant (DQ2-g-VI: QLP
FPQQPQ) (Qiao et al., 2005).
These data demonstrate that (1) identical glutamine-rich
g- and u-gliadin sequences can be deamidated to gener-
ate commonly recognized determinants in both HLA-
DQ2- and HLA-DQ8-associated celiac disease, and (2)
subdominant g- and u-gliadin determinants in HLA-
DQ8-associated celiac disease also share the synergistic
deamidation enhancement of the DQ8-a-I determinant, in
which deamidation of P1 and P9 together shows greater
T cell activity than does that of P1 or P9 alone.
DQ8-a-I Isotypic Variants Show P1 and P9
Deamidation Dependence
The TG2-treated DQ8-a-I-containing peptide a2:226–240
stimulated almost half of the IFN-g-ELISPOT response of
deamidated a-gliadin (Figures 1B and 2A). Notably, this
determinant is derived from a common sequence re-
peated in many members of the a- and b-gliadin family
of polypeptides, but it shows subtle isotypic amino acid
variation from the a2:226–240 sequence. Hence, we
Immunity
HLA DQ8 and Celiac DiseaseFigure 4. Conformation of the Deamidated a2 Gliadin:223–240 within the Antigen-Binding Cleft of HLA DQ8
(A) The a2 gliadin:223–240 Q229E Q237E peptide is shown in yellow-ball-and-stick format along with the DQa (purple) and DQb (blue) chains.
(B) The peptide’s corresponding 2Fo-Fc electron density contoured at 1s with amino acid residues labeled. Only peptide residues 227–239 (P2 to
P11) have been modeled, because electron density for these residues was clear and unambiguous. The HLA DQ8 antigen-binding groove is shown
in gray ribbon format. The b-helix of the peptide-binding groove has been removed for visibility.
(C) Surface representation showing the electrostatic potential of HLA DQ8 with the bound a2 gliadin:223–240 Q229E Q237E peptide. The electrostatic
surface potential of HLA DQ8 was generated with GRASP (graphical representation and analysis of structural properties; electronegative areas in red,
electropositive in blue). The bound a2 gliadin:223–240 Q229E Q237E peptide is shown in white ball-and-stick format with amino acids labeled. The
glutamate side chains at P1 and P9 are shown in yellow and, along with the phenylalanine at P4, are buried in deep pockets anchoring the peptide in
the antigen-binding groove.evaluated T cell reactivity against two naturally occurring
isotypic variants of a2:226–240, containing the substitu-
tion P235S (P6 in DQ8-a-I) alone (CAB 76954 200–214)
or in combination with G231V (P2 in DQ8-a-I) (AAA
34283 213–233) (Figure 3B). The substitution P235S to-
gether with glutamate substitutions Q229E (P1) and
Q237E (P9) resulted in a peptide that was 100-fold more
potent than the wild-type peptide containing glutamines
and was approximately 10%–30% as potent in T cell stim-
ulation as a2:226–240 Q229E Q237E. Dual substitutions,
P235S and G231V, abolished bioactivity with or without
deamidation. These findings suggest that some, but per-
haps not all, isotypic variants of a2:226–240 can stimulate
T cells on gluten challenge in HLA-DQ8-associated celiac
disease. These isotypic analogs possess the same P1 +
P9 deamidation enhancement as does the wild-type
DQ8-a-I-containing peptide a2:226–240.
The Structure of HLA DQ8SGEGSFQPSQENP
To provide a structural basis for the increased immunoge-
nicity of P1 and P9 deamidated gliadin peptides in
HLA-DQ8-associated celiac disease, we determined the
2.1 A˚ resolution structure of HLA DQ8 in complex with
the DQ8-a-I-containing a2:223–240 Q229E Q237E
(QQYPSGEGSFQPSQENPQ) peptide to an Rfac and
Rfree of 21.7% and 24.9%, respectively. Clear and unam-
biguous electron density was seen for 13 of the 18 peptideresidues (residues 227–239 SGEGSFQPSQENP), as well
as those residues contacting the antigen. The structure
of HLA DQ8SGEGSFQPSQENP is consistent with previously
determined major histocompatability complex (MHC)
class II structures (Figure 4A). Accordingly, the HLA
DQ8SGEGSFQPSQENP structure superposes well onto the
previously determined HLA-DQ8-insulin peptide structure
(root-mean-square [rms] deviation of 0.72 A˚ over all
Calpha atoms), with substantial differences attributable
principally to the different peptides bound in the antigen-
binding cleft. Approximately 84% of the core peptide
(P1–P9, EGSFQPSQE) is buried upon complexation to
HLA DQ8, a value that falls within the range of other class
II peptide complexes.
The peptide binds in an extended conformation within
the HLA DQ8 antigen-binding cleft, adopting a left-handed
helical conformation that resembles a polyproline type II
helix (Figure 4B). The bound peptide, occupying positions
P2 to P11 within the cleft, makes many contacts with HLA
DQ8, forming four salt bridges, 16 direct hydrogen bonds,
and 24 water-meditated hydrogen bonds (Table S3 and
Figure S2). The side chains of P1-Glu, P4-Phe, and P9-
Glu are bound in deep pockets, forming major anchor res-
idues, whereas side chains from the P6-Pro and P7-Ser lie
in shallow pockets, forming minor anchor residues
(Figure 4C). P4-Phe was observed to make many interac-
tions with the residues lining this large and hydrophobicImmunity 27, 23–34, July 2007 ª2007 Elsevier Inc. 29
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and P9 of the HLA-DQ8-Restricted Glia-
din Peptides
(A and C) The binding interactions between the
peptide’s P1 (A) and P9 (C) glutamate residues
and the HLA DQ8 P1 and P9 pockets, respec-
tively, are shown. Peptide residues P1 to P2 (A)
and P8 to P10 (C) are shown in yellow ball-and-
stick format with the P1 and P9 glutamate (‘‘E’’)
residues labeled.
(B and D) Hypothetical binding interaction
within the P1 pocket (B) and P9 pocket (D)
when glutamate is modeled as a glutamine at
these positions, as in the nondeamidated
form. Peptide residues P1 to P2 (B) and P8 to
P10 (D) are shown in green ball-and-stick for-
mat with the P1 and P9 glutamine (‘‘Q’’) resi-
dues labeled. HLA DQ8 P1 and P9 pocket res-
idues mediating the interactions are labeled
and shown in gray ball-and-stick format. Water
molecules are shown as blue spheres. Hydro-
gen bonds and salt bridges are shown as black
and pink dashed lines, respectively.pocket. Twelve of the sixteen hydrogen bonds are formed
between the peptide backbone and HLA DQ8, eight of
which are conserved in most MHC class II structures
and are mediated via Arg53a, Asn62b, Asn69b, Trp61b,
Asn82b, and His81b (Stern et al., 1994). Of note however,
is that HLA DQ2 lacks the Arg53a residue and perhaps for
this reason does not make a hydrogen bond between the
amide nitrogen of P1 and the backbone carbonyl of
Arg53a. As a result, HLA DQ2 is more adapted to tolerat-
ing a proline residue at P1 than is HLA DQ8.
The Tyr9Aa residue represents an insertion found in all
DQ and IA molecules and forms a b-bulge structure, en-
abling it to form a hydrogen bond with the amide nitrogen
of the P4-Phe (Fremont et al., 1998; Scott et al., 1998). This
bond might serve to pull the peptide down, accounting for
the more pronounced dip in the middle of the peptides that
are seen in DQ and IA molecules.
The glutamine residues at P5 and P8 exhibit high sol-
vent accessibilities (51% and 58%, respectively), with
their side chains projecting out of the cleft, and hence
are available for T cell receptor (TCR) ligation (Figure 4B).
Further evidence for their involvement in mediating TCR
contact comes from studies that show that T cell activity
is abolished when these residues are deamidated (van
de Wal et al., 1998a). In addition, the flanking residues
P(-)2-Ser, P(-)1-Gly, P10-Asn, and P11-Pro might also
play a role in TCR recognition because they too exhibit
high solvent accessibilities. Interestingly, a study with a2
gliadin peptide bound to HLA DQ8 revealed a critical
role for the N-terminal flanking residues P(-)2-Ser and
P(-)1-Gly and the C-terminal flanking residue P10-Asn in
T cell activation (van de Wal et al., 1998b). Collectively,
these results reveal the mode of binding of this immuno-30 Immunity 27, 23–34, July 2007 ª2007 Elsevier Inc.dominant gliadin determinant to HLA DQ8, confirming
the anchor roles of the deamidation-susceptible P1 and
P9 residues.
Structural Basis for Increased Immunogenicity
of Deamidated Gluten Peptides
The peptide-binding motif for HLA DQ8 has been previ-
ously characterized as having a preference for negatively
charged residues at P1 and P9 (Moustakas et al., 2000),
and this is consistent with the necessity of two deamida-
tion steps of the immunodominant gliadin determinant to
create glutamate residues at these sites. The P1 pocket
is a deep and highly charged pocket that is lined with
four charged residues (His24, Arg52, Glu31, and Glu86)
(Figure 5A). In the P1 pocket, the P1-Glu forms two salt
bridges with Arg52 and also forms water-mediated hydro-
gen bonds with His24, Glu31, and Arg53. Because the
Arg52 is situated near the top of the pocket, the side chain
of P1-Glu does not extend fully into the base of the pocket
and thus avoids electrostatic repulsion from the two gluta-
mate residues that line this pocket (Figure 5A). The P9
pocket is positively charged due to the presence of
His68 and Arg76. Within this pocket, the P9-Glu forms
two salt bridges with Arg76, which is situated at the
base of the pocket with its side chain extended up into
pocket 7b. In most other class II molecules, the Arg76a
forms an interchain salt bridge with Asp57b; however, in
HLA DQ8, the interchain salt bridge is lost because of
the replacement of Asp57b with alanine (Lee et al.,
2001). The P9-Glu also forms a hydrogen bond to Tyr27
(Figure 5).
If glutamate were substituted for glutamine at either of
the P1 or P9 positions in the DQ8-a-I gliadin determinant,
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ing network within these respective pockets would be dis-
rupted (Figures 5B and 5D). Within both pockets, the sta-
bilizing salt bridges would be replaced by hydrogen bonds
(with the loss of one bond in the P1 pocket), invariably re-
sulting in a weaker interaction between the peptide and
HLA DQ8, thereby leading to a less stable complex. There-
fore, the heightened immunogenicity of the deamidated
determinants is consistent with the ability of these pep-
tides to bind more strongly to HLA DQ8 (Figure S1) than
their nondeamidated counterparts.
DISCUSSION
Most of our understanding of celiac disease derives from
studies in Europeans, among whom more than 90% are
HLA DQ2+ (Karell et al., 2003), whereas about 5% possess
HLA DQ8 without HLA DQ2. In comparison, HLA DQ2 is
present in about 20% of the general population, and
HLA DQ8 in about 10%. Here we show that the molecular
basis for HLA-DQ8-associated celiac disease is distinct
from that for HLA-DQ2-associated disease. Accordingly,
it is also an intriguing possibility that sero-diagnostics as-
sessed and optimized in predominantly Caucasian popu-
lations, in which HLA-DQ2-associated celiac disease pre-
dominates, might not be as effective in communities in
which HLA DQ2 is rare and HLA DQ8 is common, such
as in East Asians, in whom celiac disease is believed to
be rare. Therefore, as atypical celiac disease is increas-
ingly recognized in clinical practice, it is important to un-
derstand the molecular pathogenesis of this disorder
(van Heel and West, 2006).
Several wheat-gluten peptides have been implicated in
the Th1-mediated immunopathology of HLA-DQ8-associ-
ated celiac disease. These include DQ8-a-I derived from
a-gliadin, DQ8-GLT-I derived from HMW glutenin (van
de Wal et al., 1998a; van de Wal et al., 1999; van de Wal
et al., 1998b), and DQ8-g-I (EQPQQPFPE) derived from
g-gliadin (Tollefsen et al., 2006). Responses to DQ8-
GLT-I are inconsistent and are not significantly enhanced
after deamidation by TG2. In contrast, T cell immunity to-
ward DQ8-a-I is generally present in HLA DQ2DQ8+ pa-
tients, where it often accounts for a significant proportion
of all T cell responses to gliadin, suggesting a degree of
immunodominance. Our data are consistent with this gen-
eralization and also demonstrate the substantial enhance-
ment of T cell reactivity toward DQ8-a-I after deamidation
by TG2. However, we also found evidence of multiple sub-
dominant T cell peptides, including DQ8-g-I, present in g-,
u-, and a- and b-gliadins that were frequently enhanced
by or dependent on deamidation. Thus, T cell-mediated
enteropathy in HLA-DQ8-associated celiac disease ap-
pears to be largely but not exclusively deamidation depen-
dent and might be driven by a mixture of a relatively dom-
inant and multiple subdominant gluten peptides.
In contrast, the HLA-DQ2-restricted peptides DQ2-a-I
(PFPQPELPY) and DQ2-a-II (PQPELPYPQ) are clearly im-
munodominant in this form of celiac disease, representing
the equivalent of about half of the T cell response todeamidated gliadin (Anderson et al., 2005). These deter-
minants might be all that is required to drive disease in
HLA DQ2+ patients (Anderson et al., 2000; Arentz-Hansen
et al., 2000). This notion is consistent with the observation
that these determinants are derived from a highly prote-
ase-resistant, proline-rich polypeptide that is preserved
in the intestinal lumen (Shan et al., 2002). Our data demon-
strate that the antigen presentation of the DQ8-a-I deter-
minant by HLA DQ8 is unlikely to tolerate a Pro at P1
and so selects other sequences that are more likely to
be sensitive to proteases, particularly aminopeptidases.
Accordingly, the DQ8-a-I determinant is from a region
that is susceptible to digestive proteases, and it might
have a short half-life and bioavailability for antigen presen-
tation; this conclusion corroborates the interpretation of
a recent study (Tollefsen et al., 2006).
Taken together, the highly immunodominant, protease-
resistant nature of the HLA DQ2 gliadin peptides might
help explain the strong association of this HLA type with
celiac disease. In contrast, the lower penetrance of celiac
disease in HLA DQ8+ individuals (Margaritte-Jeannin
et al., 2004) might partly be explained by the less dominant
nature of the main T cell determinant(s) and its (or their) rel-
ative protease sensitivity. Of course, other genetic factors
are likely to be involved in susceptibility to celiac disease,
and some of these might map to the MHC in linkage dis-
equilibrium with HLA DQ alleles.
The HLA-DQ2-associated and HLA-DQ8-associated
forms of celiac disease appear to differ in the patterns of
deamidation dependence of peptide determinants for op-
timal T cell reactivity. In HLA-DQ2-associated celiac dis-
ease, the gluten determinants are modified by a single
deamidation step. Similarly, T cell responses in the HLA-
DQ8-associated celiac disease were also shown to be
deamidation dependent; however, in the case of the im-
munodominant DQ8-a-I determinant, optimal deamida-
tion steps must occur at positions P1 and P9 (van de
Wal et al., 1998a). This pattern of deamidation enhance-
ment involving dual residues at P1 and P9 was also
evident in several subdominant g- and u-gliadin T cell
determinants. Thus, in contrast to the single glutamine-
to-glutamate modification necessary for T cell responses
in HLA-DQ2-associated celiac disease, T cell reactivity
in HLA DQ8+ patients shows a hierarchical enhancement
of responsiveness with P1-Glu+P9-Glu > P1-Glu/P9-
Gln = P1-Gln/P9-Glu > P1-Gln/P9-Gln. This more demand-
ing preference for deamidation of the dominant HLA-DQ8-
restricted determinant at two sites might also contribute to
the lower penetrance of celiac disease in HLA DQ8+
versus HLA DQ2+ individuals, especially given the prote-
ase-sensitive nature of the a2-gliadin polypeptide that
contains DQ8-a-I.
The high-resolution crystal structure of HLA DQ8 bound
to the dominant DQ8-a-I-containing peptide (QQYPSG
EGSFQPSQENPQ) allows us to establish experimentally
the structural basis for this pattern of preferred determi-
nant selection, with the presence of glutamates at P1
and P9 enabling buried salt-bridging interactions with
HLA DQ8. Although the energetic contributions ofImmunity 27, 23–34, July 2007 ª2007 Elsevier Inc. 31
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drogen bond and a buried salt bridge typically contribute
0.6–1.6 kcal/mol and 3–5 kcal/mol, respectively (Ander-
son et al., 1990; Pace et al., 1996). Accordingly, our struc-
tural and stability data are consistent with deamidation’s
generating a more stable HLA DQ8 complex compared
to that of its nondeamidated counterpart.
Indeed, the HLA DQ8 determinants would appear to be
better HLA binders (both in their native and deamidated
states) than their counterparts that bind to HLA DQ2.
Moreover, some subdominant gluten determinants re-
quire only one deamidation step to elicit a T cell response,
whereas with others, no modification was required at all,
suggesting that at least for some HLA-DQ8-associated
determinants the role of transglutaminase appears to be
less critical for functionality. In addition, the presence of
fewer proline and glutamine residues within certain HLA-
DQ8-specific determinants suggests that treatment with
prolyl- and glutaminyl-endopeptidases might not be
a tractable intervention in this disease.
Our data indicate a distinct molecular basis for the role
of HLA DQ8 versus HLA DQ2 in the pathogenesis of celiac
disease and that promising therapeutic strategies pro-
posed for the latter might not be appropriate for HLA
DQ8 celiac disease.
EXPERIMENTAL PROCEDURES
Subjects and Antigen Challenge
The study was approved by the Oxfordshire Regional Ethics Commit-
tee and Melbourne Health Human Ethics Committee. HLA DQB and
HLA DQA genotyping (Bunce et al., 1995; Mullighan et al., 1997;
Olerup et al., 1993) of 91 subjects in Oxford and 204 celiac disease
subjects in Melbourne identified 12 (five in Oxford and seven in
Melbourne) that possessed HLA DQ8 (HLA DQA1*03 and HLA
DQB1*0302) but not genes encoding HLA DQ2 (either HLA DQA1*05
or HLA DQB1*02), among whom five underwent the gluten challenge.
Blood from two further celiac subjects who possessed both HLA DQ2
and DQ8 but did not undergo the gluten challenge was used to clone
T cells. Celiac disease was diagnosed according to European Society
for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
criteria. Clinical characteristics of subjects are shown in Table 1. The
gluten challenge consisted of two 50 g slices of gluten-containing
wheat bread consumed twice daily for three days or as tolerated.
Antigens
Individual synthetic peptides (purity > 70%) were purchased from Re-
search Genetics (Huntsville, Alabama), Mimotopes (Melbourne, Aus-
tralia), or Pepscan (Lelystad, Netherlands). The gliadin 20-mer peptide
library was designed to encompass all unique sequences of 12 amino
acids in 108 entries for Triticum aestivum a-, b-, g-, and u-gliadins
found by searching NCBI GenBank (July 2003), as described else-
where (Beissbarth et al., 2005). The 1 mmol 721-member 20-mer library
was synthesized in batches of 96 peptides as Pepsets (Mimotopes).
Two marker 20-mers were included in each set of 96 peptides that
were characterized by reverse-phase-HPLC and amino acid-
sequence analysis, with median purity of 61%. Peptides were initially
dissolved in 50% aqueous acetonitrile (v:v) to 25 mM (50 mg/ml).
Deamidation of peptides and prolamins with guinea pig liver TG2
(Sigma T5398) was as described previously (Anderson et al., 2000).
Prolamin Preparation
Lyophilized gliadin (total gliadin) (including albumins and globulins)
was prepared from filtered, chloroform-defatted white wheat flour32 Immunity 27, 23–34, July 2007 ª2007 Elsevier Inc.that was twice extracted with 70% ethanol and dialyzed against 1%
aqueous acetic acid. The total gliadin was fractionated into u-, a-,
b-, and g-gliadin fractions by ion-exchange chromatography with car-
boxymethyl cellulose (CMC, cation exchanger) buffered with 10 mM
glycine acetate (pH 4.6) and containing 3M urea. Gliadin-containing
fractions identified by ultraviolet (UV) absorbance at 215 nm were
eluted in a series of linear and isocratic steps with increasing concen-
trations of saline. Pooled fractions corresponding to peaks were dia-
lyzed six times against 1% acetic acid and then lyophilized. The iden-
tity of gliadin fractions was confirmed with 10% lactate-PAGE
(polyacrylamide gel electrophoresis) gels and 12.5% Laemmli gels.
Secalins were prepared from rye seed that was hand sorted to remove
contaminating seeds (mainly wheat and barley) and milled on a labora-
tory mill to yield white flour. The methodology was similar to that of the
wheat-gluten proteins. Rye flour was defatted with Pet Ether (40C–
60C) twice and air dried; this was extracted with 0.5 M saline to
remove albumins and globulins (twice) and then extracted with 50%
(v/v) propan-1-ol, 2% acetic acid (v/v), and 2% 2-mercaptoethanol
at room temperature for 1 hr (twice). The mixture was centrifuged,
and the clear supernatant was dialyzed against 1% acetic acid for
60 hr. The protein was precipitated and collected by centrifugation.
This was freeze dried and dissolved in 8 M urea, 1% 2-mercaptoetha-
nol, and 1% acetic acid and purified by reverse-phase high-perfor-
mance chromatography (RP-HPLC). Fractions were checked for purity
by sodium dodecyl sulfate (SDS)-PAGE.
IFN-g ELISPOT
PBMCs were prepared from venous blood by Ficoll-Hypaque density
centrifugation. After three washes in phosphate buffered saline (PBS),
PBMCs were resuspended in complete RPMI containing 10% heat-
inactivated human AB serum. ELISPOT assays for single-cell secretion
of IFN-g were performed with commercial kits (Mabtech [Stockholm,
Sweden]) with 96-well plates (MAIP-S-45; Millipore [Bedford, Massa-
chusetts]) according to the manufacturers’ instructions (Anderson
et al., 2000). Peptides were assessed in single wells, and tetanus tox-
oid (Commonwealth Serum Laboratories [CSL, Melbourne]) (10 light-
forming unit (LFU)/ml) was used as a positive control in all assays.
SFUs in individual wells were counted with an automated ELISPOT
reader (AID ELISPOT Reader System, AID Autoimmun Diagnostika
GmbH [Strassberg, Germany]).
MHC Class II Blocking
HLA-class II restriction was established by the incubation of PBMCs
with 10 mg/ml azide-free mouse anti-HLA-DR IgG (clone L243;
555809, PharMingen [San Diego, California]) or anti-HLA DQ (clone
SPvL3; MCA37G, Serotec [Oxford, UK]) at 37C for one hour prior to
the addition of peptide.
T Cell Clones
The method of Mannering et al. (2005) was used to isolate HLA DQ8 re-
stricted T cell clones from PBMCs of two HLA DQ2+DQ8+ donors on the
gluten-free diet. PBMCs were labeled with carboxyfluorescein succini-
midyl ester (CFSE) and incubated for one week with a2:223–240 Q229E
Q237E prior to the single-cell sorting of CFSElow CD4+ T cells.
In Vitro HLA DQ8 Binding Assay
The method was adapted from that described by Vader et al. (2003b).
Flat-bottom 96-well plates (Greiner) were coated with 100 ml/well of the
HLA-DQ-specific mAb SPvL3 at 20 mg/ml in 50 mM sodium carbonate
buffer (pH 9.6) for 2 hr at 37C. Wells were washed and blocked with
0.2% bovine serum albumin (BSA) in PBS overnight at 4C. Lysates
of the Epstein-Barr virus (EBV)-transformed HLA-DR4-DQ8 homozy-
gous B lymphoblastoid cell line 9031 were prepared by the incubation
of washed cells (2 3 106/ml) in 20 mM Tris HCl (pH 7.5), 5 mM MgCl2,
and 1% IGEPAL and protease inhibitors (complete cocktail tablets,
Roche). Cell debris was removed by centrifugation, and 100 ml/well
of lysate was added to blocked plates overnight at 4C. Wells were
washed, and the indicator peptide CLIP (LPKPPKPVSKMRMAT
Immunity
HLA DQ8 and Celiac DiseasePLLMQ) was added to a final concentration of 2 mM in binding buffer
(5% DMSO, 0.05% IGEPAL, 0.05% Tween 20, 16.8 mM citric acid,
and 36 mM Na2HPO4 (pH 5.5) and protease inhibitors). For competi-
tion, test peptides were added at a 3- to 100-fold molar excess in
the presence of CLIP peptide, and plates were incubated for 48 hr at
37C. Plates were washed and incubated with neutravidin horseradish
peroxidase (HRP) (Pierce) in binding buffer for 1 hr at room tempera-
ture, and development with o-phenylenediamine dihydrochloride
(Sigma) and detection in a Varioskan plate reader (Thermo) followed.
Protein Expression, Crystallization,
and Structure Determination
HLA DQ8 was expressed, purified, and crystallized (unpublished data).
In brief, HLA DQ8 was expressed from Baculovirus, purified, and con-
centrated to 7 mg/ml. Crystals were obtained with 0.05 M monopotas-
sium dihydrogen phosphate and 19% (w/v) polyethylene glycol (PEG)
8000 as the precipitant. The crystals were flash frozen prior to data col-
lection with 20% glycerol as the cryoprotectant. A 2.1 A˚ data set was
merged and scaled with d*TREK. The crystals belong to the space
group P212121, with unit cell dimensions a = 58.83 A˚, b = 92.52 A˚,
andc= 133.06, and with a solvent content consistent with one molecule
per asymmetric unit. The structure of HLA DQ8 was determined by
molecular replacement with the program AMORE (CCP4). The insulin
peptide-HLA DQ8 complex (Protein Data Bank [PDB] ID code IJK8), mi-
nus the insulin peptide and solvent molecules, was used as a search
probe (Lee et al., 2001). One clear solution was found, and unbiased
features in the initial electron-density map confirmed the correctness
of the molecular-replacement solution. The structure was refined with
the simulated annealing protocol as implemented in CNS, interspersed
with rounds of model building with the program ‘‘O’’. During refinement,
neither a sigma nor a low-resolution cutoff was applied to the data. The
process of refinement was monitored by theRfree value (4% of the data).
Water molecules were included in the model if they were within hydro-
gen-bonding distance to chemically reasonable groups and appeared
in the Fo-Fc maps contoured at 3s. The final model includes 375 amino
acids (a chain, 2–180; b chain, 1–103 and 114–190; a2-gliadin, 227–
239; one linker glycine and serine) and 311 water molecules. See Table
S4 for a summary of data collection and refinement statistics. The
coordinates have been deposited in the PDB, code 2NNA.
Supplemental Data
Two figures and four tables are available at http://www.immunity.com/
cgi/content/full/27/1/23/DC1/.
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